Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$2.21 USD
-0.08 (-3.49%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $2.22 +0.01 (0.45%) 5:06 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 161 - 180 ( 270 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
After a Rough Start, Opportunities Begin to Stand Out
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals - January and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
RG-125 for NASH Enters the Clinic, Earning Regulus a $10MM Milestone Payment; Reiterate OUTPERFORM and $42 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
December 2015 and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 23
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
AASLD Review: Updated Phase 1 Results for RG-101 Further Support Ongoing Combination Study; Reiterate OUTPERFORM and $42 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q3 Results In Line; Multiple Potential Inflection Points in Next 6-12 Months; Reiterate OUTPERFORM and $42 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
GSK Collaboration Could Develop a Single Office Visit Cure for HCV; Reiterate OUTPERFORM and $42 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
November and Remaining 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Corporate Update and ASN Preview of RG-012 and Alport Syndrome; Reiterate OUTPERFORM and $42 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 2This report contains brief updates on the following: DYAX, ANAC, IRWD, ECYT, FATE, XNCR, RGLS, MGNX, FCSC, SNSS, INFI, MDVN, RPTP, SRPT, XOMA, AGTC, EPZM, BLUE, PTCT, CATB, EPRS, ABUS, ICPT. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of October 12
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
October and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
October and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
September and 2015 Catalysts for Emerging PharmaceuticalsThis report contains brief updates on the following: BIOD, BMRN, CBYL, ICPT, LXRX, OMER, PCRX, RGLS, RLYP, SGMO, UTHR, VTAE, XOMA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals: September and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q2 Financials: Cash Through 2016 and Material Catalysts in 2015; Reiterate OUTPERFORM and Increasing PT to $42 for Time Value.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L